Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 7/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 4/20 | 0.41 |
| ▸ | SI | P14410 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | GLB1 | P16278 | 1/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.36 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.36 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TREH | O43280 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | LCT | P09848 | 1/20 | 0.36 |
| ▸ | AGL | P35573 | 1/20 | 0.36 |
| ▸ | GANAB | Q14697 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18523022 | 1.00 | GBA1 (0.41) | GBA1GBA2SIGAAPYGL | |
| SCHEMBL22631740 | 1.00 | GBA1 (0.41) | GBA1GBA2SIGAAPYGL | |
| SCHEMBL18962605 | 1.00 | GBA1 (0.41) | GBA1GBA2SIGAAPYGL | |
| SCHEMBL16785937 | 1.00 | GBA1 (0.41) | GBA1GBA2SIGAAPYGL | |
| SCHEMBL18707465 | 1.00 | GBA1 (0.41) | GBA1GBA2SIGAAPYGL | |
| SCHEMBL13425150 | 1.00 | GBA1 (0.41) | GBA1GBA2SIGAAPYGL | |
| SCHEMBL16168335 | 0.97 | SI (0.44) | GBA1GBA2SIGAAPYGL | |
| SCHEMBL260181 | 0.92 | — | — | |
| SCHEMBL12329241 | 0.92 | — | — | |
| SCHEMBL12463717 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020046132-A1 | PHARMACOLOGICAL CHAPERONES FOR ENZYME TREATMENT THERAPY | LEIDEN UNIVERSITY (NL) | 2020-03-05 | — | — | WO | disclosed |
| US-20170226058-A1 | N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | Stichting Amsterdam UMC (NL) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226058-A1 | N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | GBA2, GBA1, GALC | GBA1 2/4885GBA2 1/4885SI 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.